Kostron H, Grunert V
Wien Klin Wochenschr. 1987 May 29;99(11):389-92.
The combination of haematoporphyrin derivative (HPD) and visible light at 630 nm, termed as photodynamic treatment (PDT), provides a new tool in tumour therapy, causing selective tumour destruction initiated by photochemical reactions. Up to now 13 patients with malignant brain tumours (12 glioblastoma multiforme, 1 leiomyosarcoma) were treated with 40-80 J/cm2 light following parenteral or direct injection of HPD (5 mg/i.a. or 1 mg/ccm tumour volume). In 5 patients the PDT was followed by subsequent radiotherapy with 4 Gy. The patients with recurrent tumour showed a median survival time of 5 months, whereas the 6 patients with primary manifestations have survived so far for periods of up to 9 months. However, the follow up period is too short to allow final conclusions to be reached on the effect of PDT in the treatment of malignant brain tumours.
血卟啉衍生物(HPD)与630纳米可见光相结合,即光动力疗法(PDT),为肿瘤治疗提供了一种新工具,通过光化学反应引发选择性肿瘤破坏。到目前为止,13例恶性脑肿瘤患者(12例多形性胶质母细胞瘤,1例平滑肌肉瘤)在经静脉注射或直接注射HPD(5毫克/颅内或1毫克/立方厘米肿瘤体积)后接受了40 - 80焦耳/平方厘米的光照治疗。5例患者在光动力疗法后接受了4戈瑞的后续放疗。复发性肿瘤患者的中位生存时间为5个月,而6例初发患者迄今为止存活时间长达9个月。然而,随访期太短,无法就光动力疗法在恶性脑肿瘤治疗中的效果得出最终结论。